1	Title
2	Clustering ICU patients with sepsis based on the patterns of their circulating
3	biomarkers: a secondary analysis of the CAPTAIN prospective multicenter
4	cohort study.
5	Short title
6	Clustering patients with sepsis
7	
8	Benoît Misset <sup>1,2*</sup> , François Philippart <sup>3,4</sup> , Catherine Fitting <sup>5</sup> , Jean-Pierre Bedos <sup>6</sup> , Jean-Luc
9	Diehl <sup>7,8</sup> , Olfa Hamzaoui <sup>9</sup> , Djillali Annane <sup>10,11</sup> , Didier Journois <sup>12</sup> , Marianna Parlato <sup>5</sup> , Virginie
10	Moucadel <sup>13</sup> , Jean-Marc Cavaillon <sup>5</sup> , Joël Coste <sup>14,15</sup> , for the Captain Study Group <sup>^</sup>
11	
12	<sup>1</sup> Intensive Care Department, Liège University Hospital, Liège, Belgium
13	<sup>2</sup> Infection, immunity and inflammation Research Unit, GIGA 13, Liège University
14	Research Unit, Liège, Belgium
15	<sup>3</sup> Service de Médecine Intensive et Réanimation, Groupe hospitalier Paris Saint-Joseph, Paris,
16	France
17	<sup>4</sup> Unité endotoxines, structures et réponse de l'hôte, Département de Microbiologie, Institut de
18	Biologie Intégrative de la Cellule, Paris Saclay, Saclay, France
19	<sup>5</sup> Unit Cytokines & Inflammation, Institut Pasteur, Paris, France
20	<sup>6</sup> Service de Réanimation, Hôpital André Mignot, Versailles, France
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to quide clinical practice.

- <sup>7</sup> Service de Réanimation Médicale, Hôpital Européen Georges Pompidou, Assistance Publique
- 22 Hôpitaux de Paris, Paris, France
- <sup>8</sup> INSERM UMR S1140, Université Paris Descartes, Paris Sorbonne Cité, Paris France
- <sup>9</sup> Service de Réanimation, Hôpital Antoine Béclère, Assistance Publique Hôpitaux de Paris,
- 25 Clamart, France
- 26 <sup>10</sup> Service de Réanimation, Hôpital Raymond Poincaré, Assistance Publique Hôpitaux de
- 27 Paris, Garches, France
- 28 <sup>11</sup> Université Versailles Saint-Quentin, Versailles, France
- <sup>12</sup> Service de Réanimation Chirurgicale, Hôpital Européen Georges Pompidou, Assistance
- 30 Publique Hôpitaux de Paris, Paris, France
- 31 <sup>13</sup> BioMérieux SA, Lyon, France
- <sup>14</sup> Unité de Biostatistiques et d'Epidémiologie, Hôpital Cochin, Assistance Publique Hôpitaux
- 33 de Paris, Paris, France
- <sup>15</sup> Université de Paris, Paris, France
- 35
- 36 \*Corresponding author:
- 37 ORCID iD : 000000164660065
- 38 e-mail: <u>benoit.misset@chuliege.be</u> (BM)
- 39
- 40 Authors' contributions:

- 41 Drs Misset, Philippart, Cavaillon and Coste had full access to all the data in the study and take
- 42 responsibility for the integrity of the data and the accuracy of the data analysis.
- 43 Study concept and design: Misset, Philippart, Cavaillon and Coste
- 44 Acquisition of data: Philippart, Fitting, Parlato, Moucadel, Bedos, Journois, Hamzaoui,
- 45 Annane, Diehl
- 46 Access to data, analysis and interpretation: Misset, Philippart, Parlato, Moucadel, Cavaillon and
- 47 Coste
- 48 Drafting of the manuscript: Misset, Philippart, Cavaillon and Coste
- 49 Critical revision of the manuscript for important intellectual content: Misset, Philippart,
- 50 Annane, Moucadel, Cavaillon and Coste
- 51 Statistical analysis: Coste
- 52 Obtained funding: Misset, Moucadel
- 53 Administrative, technical, or material support: Fitting
- 54
- 55
- <sup>56</sup> <sup>^</sup>Members of the Combined Approach for The eArly diagnosis of INfection in sepsis
- 57 (CAPTAIN) study group is provided in the Acknowledgments (collaborators section).

## 58 Abstract

#### 59 Background

Although sepsis is a life-threatening condition, its heterogeneous presentation likely explains
 the negative results of most trials on adjunctive therapy. This study in patients with sepsis aimed

to identify subgroups with similar immune profiles and their clinical and outcome correlates.

#### 63 Methods

62

A secondary analysis used data of a prospective multicenter cohort that included patients with early assessment of sepsis. They were described using Predisposition, Insult, Response, Organ failure sepsis (PIRO) staging system. Thirty-eight circulating biomarkers (27 proteins, 11 mRNAs) were assessed at sepsis diagnosis, and their patterns were determined through principal component analysis (PCA). Hierarchical clustering was used to group the patients and *k*-means algorithm was applied to assess the internal validity of the clusters.

## 70 **Results**

Two hundred and three patients were assessed, of median age 64.5 [52.0-77.0] years and SAPS2 score 55 [49-61] points. Five main patterns of biomarkers and six clusters of patients (including 42%, 21%, 17%, 9%, 5% and 5% of the patients) were evidenced. Clusters were distinguished according to the certainty of the causal infection, inflammation, use of organ support, pro- and anti-inflammatory activity, and adaptive profile markers.

#### 76 Conclusions

In this cohort of patients with suspected sepsis, we individualized clusters which may bedescribed with criteria used to stage sepsis. As these clusters are based on the patterns of

circulating biomarkers, whether they might help to predict treatment responsiveness should beaddressed in further studies.

#### 81 Trial registration

The CAPTAIN study was registered on clinicaltrials.gov on June 22, 2011, # NCT01378169.

83

## 84 Introduction

Sepsis is a clinical picture of organ dysfunctions elicited by an infection, and associated with 85 immune dysregulation [1]. Its mortality varies between 25 and 60 % [2, 3]. The intensity of the 86 organ dysfunctions are usually assessed by the SOFA score [4]. Immune dysregulation is 87 complex and not fully deciphered [5], follows from the activation by both pathogen and danger-88 associated molecular patterns [6], and is associated with a variety of immune pathways 89 including inflammation, compensatory anti-inflammation, and low adaptive profile [7, 8]. It is 90 likely dependent on underlying diseases [9], genetic predisposition [10] and the causal agent of 91 92 infection [11]. All these dimensions of sepsis are included in the Predisposition, Insult, Response, Organ failure sepsis (PIRO) classification system, a tool proposed in 2001 to 93 characterize and stage sepsis [12]. As numerous trials failed to improve unselected cohorts of 94 patients with sepsis [13, 14], "endotypes" describing patient groups with similar genetic, 95 epigenetic or proteomic pattern, have been proposed [15]. They are excepted to help to predict 96 treatment responsiveness and not just differences in prognosis [16]. Endotyping aims at 97 categorizing the different pathways involved [14, 16] in order to select patients as potential 98 targets of specific treatments [17, 18]. Data on endotypes are scarce because the collection of 99 100 many biomarkers is not available in daily routine [19]. To comply with the recommendations of the surviving sepsis campaign [3], sepsis must be suspected and treated before the infection 101 is confirmed, and biomarkers might help to differentiate patients with bacterial infection from 102

those with other causes of immune dysregulation [20]. A better understanding of subgroups
within the heterogeneous host response to infection is important both for a better understanding
of the biology of sepsis but also for the next generation of trials of more precise interventions
for sepsis.

In a multicenter prospective cohort called CAPTAIN that included patients with suspected sepsis for whom circulating proteins or mRNAs from circulating leukocytes were assessed, these biomarkers were not able to discriminate patients with *versus* without a documented causal infection [21]. Then, we hypothesized that a clustering approach may help defining subgroups of similar patients in multidimensional populations.

112 In the present study, using the same cohort of patients with sepsis, we aimed at identifying 113 homogeneous subgroups in terms of circulating biomarkers, and clinical phenotypes and 114 mortality correlates.

115

## 116 Methods

## 117 Study design

This study is a secondary analysis of the observational multicenter prospective CAPTAIN study
(Combined Approach for The eArly diagnosis of INfection in sepsis) [21]. It was designed and
conducted according to STROBE (STrengthening the Reporting of OBservational studies in
Epidemiology) guidelines (S1 Table) [22].

122

## 123 Ethics and study registration

124	The protocol was approved by the "Comité de Protection des Personnes Ile de France XI"
125	(#2010-A00908-31-10056) on September 13, 2010 and registered on clinicaltrials.gov
126	(NCT01378169) https://clinicaltrials.gov/ct2/show/NCT01378169 . According to French national
127	regulations, written consent of the patients was required but waived for the unarousable ones,
128	and obtained if the study still required specific samples when the patient awoke.

## 129

### 130 Setting

Patients were recruited from December 2011 to April 2013 in seven ICUs from five hospitalsin Paris area.

133

#### 134 **Participants**

Eligible ICU patients were those patients with suspected sepsis. The inclusion criteria were hypothermia (below 36.0°C) or hyperthermia (over 38.0 °C), and at least one criterion of systemic inflammatory response syndrome (SIRS) [12] as soon as the physician considered antibiotic therapy. Other inclusion criteria were age over 18 years, no treatment limitation and no obvious immunosuppression.

Demographics, reasons for ICU admission, underlying diseases, simplified acute severity score (SAPS 2) [20], physiological data, Sequential Organ Failure Assessment (SOFA) score [21] and length of organ failure support were collected at admission to the ICU, at inclusion in the study and over the ICU stay. The population characteristics have been published previously [21]. Briefly, 363 patients were screened and 279 included. Based on the data obtained in the rouge after inclusion, infection could not be ascertained in one third of the patients after

adjudication by two investigators who were blind to the biomarkers. The biomarkers were found 146 to discriminate poorly between patients with versus without a documented causal infection [21]. 147 The present analysis focused on those patients who were still in ICU after day 3, because we 148 149 wanted to describe their clinical phenotypes during at least the first three days of the syndrome. We excluded those patients having not at least one available value for all the 38 biomarkers 150 collected in the first two days of inclusion because principal component analysis (see below) 151 does not handle with missing data, leading to 203 patients available for analysis. All included 152 patients had a recent increase of the total SOFA score and fulfilled the characteristics of the 153 Sepsis-3 definition [1] despite being included before its publication. 154

155

#### **Biomarkers assessment**

We collected whole blood samples at day 0 and 1 of inclusion to assess 38 biomarkers, reported 157 as potential indicators of infection or mortality during sepsis [23]. They were measured using 158 various techniques: ELISA for galectin, peptidoglycan, visfatin (previously known as pre-B 159 cell colony-enhancing factor (PBEF), soluble B7-H6 (sB7-H6), soluble Triggering Receptor 160 Expressed on Myeloid cells-1 (sTREM-1), soluble urokinase-type Plasminogen Activator 161 Receptor (suPAR) and Pancreatic Stone Protein (PSP); Bioplex technique for C-Reactive 162 Protein (CRP), ferritin, Granulocyte-Colony Stimulating Factor (G-CSF), chemokines: GRO 163 alpha (GRO-α/CXCL1), Monocyte Chemo-attractant Protein 1 (MCP-1/CCL2), Macrophage 164 Inflammatory Protein-1 alpha (MIP-1a/CCL3), Macrophage Inflammatory Protein-1 beta 165 166 (MIP-1β/CCL4), Regulated upon Activation Normal T-cell Expressed and Secreted (RANTES/CCL5), IFN-y-induced protein 10 (IP-10/CXCL10); Interferon gamma (IFN-y), 167 Interleukin-1 Receptor antagonist (IL-1Ra), Interleukins 6, 8, 10, 15, and 18 (IL-6, IL-8, IL-10, 168 169 IL-15 and IL-18), Macrophage-Colony Stimulating Factor (M-CSF), Macrophage Migration

Inhibitory Factor (MIF), Matrix Metallo Proteinase-8 (MMP-8), Procalcitonin (PCT), and 170 171 Tumor Necrosis Factor (TNF); and Real Time quantitative Polymerase Chain Reaction (RTqPCR) for the following whole blood mRNAs: Cluster of Differentiation 3δ and 74 (CD3D and 172 CD74), CX3 chemokine receptor 1 (CX3CR1), Human Leucocyte Antigen DR-alpha chain 173 (HLA-DR), High Mobility Group Box 1 protein (HMGB1), IL-1B, IL-10, Leukocyte 174 Immunoglobulin-Like Receptor subfamily B member 2 (LILRB2), S100 calcium-binding 175 protein A9 (S100A9) and TNF. Of these biomarkers, IL-1Ra, IL-10 and IL-10 mRNA are 176 considered as anti-inflammatory, HLA-DR mRNA, CD74 mRNA, CD3 mRNA and LILRB2 177 mRNA as markers of adaptive immunity, and peptidoglycan as a pathogen-associated 178 179 molecular pattern. All other above-mentioned biomarkers are considered as mediators or markers of inflammation. 180

Plasma (EDTA) was prepared at reception, aliquoted and frozen. Concentrations of plasma 181 182 markers were determined at the end of the study by sandwich ELISA or by Multiplex analysis according to manufacturers' recommendations (S2 Table). All the plasma and cell surface 183 markers were purchased from providers, except Soluble B7-H6 (S2 Table). All primers and 184 probe for the RNA markers were designed internally and purchased from Eurogentec. However, 185 primers and probe (different designs) can also be bought from some providers like 186 187 ThermoFisher, Limits of quantification are provided in S3 Table. For biomarkers whose value was below the lower limit of quantification (LLoQ), we attributed a value of LLoQ /  $\sqrt{2}$ . For 188 biomarkers whose value was over the upper limit of quantification (ULoQ), we attributed the 189 ULoQ value. The distribution of missing values and determination of the cut-off to create binary 190 variables are provided in S1 Fig. PAXgene® blood samples were incubated at room 191 temperature for 2 hours before freezing. RNA was extracted using the PAXgene® blood RNA 192 kit (PreAnalytix) and frozen at -80°C. Two hundred nanograms RNA were reverse transcribed 193 (RT) using the SuperScript® VILO<sup>™</sup> cDNA Synthesis Kit (Life Technologies) at the end of 194

the study. A RNA calibrator made from PAXgene® samples collected from a pool of healthy 195 196 volunteers and stimulated ex vivo by LPS was used in each RT run. cDNA was then diluted at 1/20 and stored at -20°C. Polymerase Chain Reaction (PCR) was performed on a LightCycler 197 instrument using the standard Tagman Fast Advanced Master Mix PCR kit according to the 198 manufacturer's instructions (Roche Molecular Biochemicals). Thermocycling was performed 199 in a final volume of 20 µL containing 0.5 µM of primers and 0.1 µM of probe (see primer and 200 probe designs in S4 Table). PCR was performed with an initial denaturation step of 10 min at 201 95°C, followed by 45 cycles of a touchdown PCR protocol (10 sec at 95°C, 29 sec annealing 202 with 68°C for the first cycle and decrease of 0.5°C for each cycle until reaching 58°C, and 1 203 204 sec extension at 72°C). The Second Derivative Maximum Method was used by the LightCycler software to automatically determine the crossing point (cycle threshold, Ct). Ct were converted 205 to Calibrated Normalized Relative Quantity (CNRQ) taking HPRT1 and PPIB as reference 206 207 genes [24].

208

### 209 Clinical phenotypes description

210 We described the patients clinical phenotypes according to the PIRO classification system [12, 25] where predispositions (P) related with chronic status and disease, insult (I) with the cause 211 of the suspected sepsis, response (R) with clinical response to this cause, and organ dysfunction 212 213 (O) with the nature and severity of the organ dysfunctions. P items were age, gender, body mass index (BMI), Mac Cabe score, chronic lung, cardiac, renal or hepatic insufficiencies, diabetes 214 or malignancy. I items were bacterial infection of the lung, abdomen or urinary tract. R items 215 were body temperature, blood lymphocyte and platelet counts, prothrombin time and serum 216 lactates as indicators of inflammatory response, coagulation activation and tissue hypoxia; 217 pneumonia or bacteremia occurring after day 5 of the ICU stay as indicators of immune 218

dysfunction. O items were sequential organ failure assessment (SOFA) and each of its sub-219 220 components (respiratory, nervous, cardiovascular, liver, coagulation and kidney dysfunctions) within two days of inclusion. Outcome was defined as the mortality at the end of the ICU stay. 221 Infections were confirmed *a posteriori*, based on criteria which confirm infection as much as 222 possible, either with or without positive cultures. The definition of infection and its causal link 223 with organ dysfunction required medical interpretation [26] and were based on IDSA guidelines 224 225 [27]. They were adjudicated blindly to the studied biomarkers, by two investigators (FP and BM). They reviewed the patients" records, including clinical history, results of routine 226 morphologic, biological, or microbiological tests, and response to therapies during the days 227 228 following inclusion. Strains were considered as infecting, colonizing or contaminants. Infection could be considered as present despite the absence of a positive microbiological sample, for 229 example in cases of abscess or pneumonia [27]. When bacteremia was present, it was linked to 230 most probable anatomical focus of infection. Viruses were only searched in case of Influenza 231 suspicion and were classified as non-septic SIRS. Disagreements on classification were 232 resolved after discussion between the two adjudicators. 233

234

235

#### 236 Statistical analysis

The determination of classes in numerical taxonomy is generally achieved by cluster analysis of a resemblance matrix, which is a combination of similarities (or distances) between all pairs of objects, *e.g.* patient's biomarkers. Here, such a simple process appeared inadequate because of the large and heterogeneous scales of biomarkers involved. Transformation and reduction of data were necessary. After adequate transformation of the data, we therefore performed a first factor analysis and further used a number of standardized factor scores for each individual asinput (in the resemblance matrix) to the clustering method.

244

#### 245 Data transformation

We determined the maximum value of the blood levels (Cmax) obtained at day 0 and day 1 of inclusion for each biomarker. For all biomarkers, these values were log-transformed to normalize their distribution and further standardized to mean 0 and unit variance.

249

## 250 Principal component analysis

To evidence patterns, Cmax of biomarkers were used to build correlation matrices (Pearson 251 252 coefficients), then studied by principal component analysis (PCA), followed by varimax rotations of retained components. The patterns obtained were uncorrelated linear combinations 253 of normalized and standardized biomarkers, and sorted by decreasing variance of rates 254 explained, whose coefficients, the "loadings", are interpretable as correlation coefficients 255 between patterns and original biomarkers. These loadings help identify the "nature" or 256 "meaning" of the patterns: "loadings" > 0.40 are usually considered to indicate substantial 257 correlation. The number of components-patterns to retain was determined by the Horn and 258 Velicer methods as recommended [28]. 259

260

## 261 Clustering

The scores of the patients on the components-patterns retained were selected for cluster analysis. Hierarchical cluster analysis (Ward method) was used to obtain the initial cluster grouping because of the lack of *a priori* knowledge of the number of clusters involved. The number of clusters selected was based on standard statistical criteria (optimal values of R2, pseudo-F, pseudo-t2 and cubic clustering criterion, which all reflect some balance between within and between cluster variances), as recommended [29].

268

#### 269 Cluster internal validity

Two methods were used to evaluate the stability and the replicability of the hierarchical cluster solution; (1) a *k*-means algorithm: this method does not assume a hierarchical relationship among clusters and allows for relocation of cases throughout the clustering process (reducing the risk of misassignment common to hierarchical cluster method [29]); (2) a subsample analysis: the hierarchical cluster analysis was repeated with a random 50% sample of the initial population to investigate whether subjects clustered similarly when they were distributed in subsamples [30].

277

#### 278 **Description of the clusters**

279 The clusters obtained were finally compared for each individual circulating biomarker and for the clinical variables usually used to describe patients with sepsis. These variables were 280 classified according to the different categories of the PIRO system to facilitate reading and 281 interpretation. For each phenotype qualitatively described, we defined two groups of patients 282 according to its presence or absence. We compared the proportions of patients in each cluster 283 with these phenotypes using non-parametric Fisher exact test. For each phenotype defined with 284 a quantitative value, we assessed correlations of the phenotype with each cluster using a 285 Spearman rank test and we compared the values of each phenotype within each cluster using 286

287	Kruskall-Wallis statistics. The quantitative values are displayed as median [Q1-Q3] and the
288	qualitative values as n (%). We considered a p-value below 0.05 for statistical significance.
289	SAS 9.4 package was used for all analysis (SAS Inst., Cary, NC, USA).
290	

291 **Results** 

#### 292 **Patients**

Out of 363 patients screened for biomarkers, 279 patients were included in the Captain cohort, 293 but 33 died or were discharged from the ICU before day 3, leading to 246 eligible patients. Of 294 these, 43 had a least one missing value among the 38 biomarkers, leading to 203 evaluable 295 patients (Fig 1). The population characteristics according to the PIRO system, are reported in 296 297 Table 1. Their median age was 64.5 [52.-77.0] years, median SAPS II score, 55 [49-61] points, and they were included 23 [11-45] hours after ICU. Among them, 189 (77%) were in the ">5-298 299 year life expectancy" category of the Mac Cabe score, 116 (47%) had underlying diseases, the 300 suspected infection was confirmed for 171 (70%). After day 5 of ICU, 26 (13%) had acquired pneumonia and 8 (4%) bacteremia. Mechanical ventilation, vasopressors, renal replacement 301 therapy and low-dose steroids were used in 182 (74%), 95 (38%), 19 (8%) and 22 (9%) patients, 302 respectively, and 58 (29%) patients died in the ICU. The levels of each single biomarker for the 303 total cohort have been published previously [21]. 304

305

306 Fig 1. Flowchart

307

#### 308 Table 1 : Characteristics of the patients, organized according to the PIRO system and

#### 309 outcome

PIRO			n (%) or med [Q1-Q3]
category		Variable	
Predisposition		Age (years)	64.5 [52.0-77.0]
		Male sex	160 (65)
		BMI (kg/m <sup>2</sup> )	25.7 [21.6-30.0]
		Mc Cabe score, % prediction > 5 years	189 (77)
		COPD	46 (19)
		Cardiac insufficiency	25 (10)
		Diabetes	53 (22)
		Chronic renal insufficiency	22 (9)
		Solid tumor	34 (14)
		Hematologic malignancy	4 (2)
		Chronic hepatic insufficiency	18 (7)
		Any prior disease	115 (47)
Insult	At inclusion	Infection due to Gram positive bacteria	76 (31)
		Infection due to Gram negative bacteria	124 (50)
		Pneumonia	123 (50)
		Intra-abdominal infection	14 (6)
		Urinary tract infection	19 (8)
		Confirmed infection	171 (70)
Response	At inclusion	Temperature (°C)	38.2 [37.5-38.8]
		Lymphocyte count (/mm <sup>3</sup> )	905 [640-1390]
		Blood platelets (10 <sup>3</sup> /mm <sup>3</sup> )	187 [134-268]

		Prothrombin time (%)	66 [59-82]
		Blood lactates (meq/L)	1.6 [1.0-2.3]
		PaO2 (mmHg)	88 [73-145]
		FiO2 (%)	40 [30-60]
		PaC02 (mmHg)	39 [34-46]
		Serum creatinin (µmol/L)	92 [71-182]
		Blood hematocrit (%)	32.2 [28.5-38.6]
		White blood cell count (/mm <sup>3</sup> )	13,200 [9,480-18,600]
		Respiratory rate (/min)	26 [22-33]
		Heart rate (/min)	106 [95-125]
		Mean arterial pressure (mmHg)	73 [63-94]
		Urinary output (L/24h)	1.30 [0.81-2.00]
		SAPS II score (points)	55 [49-61]
	After ICU day 5	ICU acquired pneumonia	26 (13)
		ICU acquired bacteremia	8 (4)
Organ failure	At inclusion	Total SOFA score (points)	6 [3-9]
		Respiratory SOFA score (points)	2 [0-3]
		Neurological SOFA score (points)	0 [0-2]
		Circulatory SOFA score (points)	0 [0-1]
		Hepatic SOFA score (points)	0 [0-0]
		Coagulation SOFA score (points)	0 [0-1]
		Kidney SOFA score (points)	0 [0-2]
	During the ICU		
	stay	Mechanical ventilation	182 (74)
		Non invasive ventilation	15 (6)
1			

Vaso-active drugs	95 (38)
Renal replacement therapy	19 (8)
Low doses steroid therapy	22 (9)

310

#### 311 Patterns of circulating biomarkers and clusters of patients

PCA of the 38 biomarkers provided five main components-patterns, which explained 30.7%, 312 9.7%, 8.0%, 5.5% and 4.7% (total 58.6%) of the variance, respectively. The biomarkers with a 313 high loading (||loading| > 0.40) are displayed in S5 Table. Pattern #1 gathers circulating 314 biomarkers and mRNAs linked to both pro- and anti-inflammatory response and to altered 315 immunity. Pattern #2 gathers only circulating biomarkers associated with pro- and anti-316 inflammatory response, and shares numerous cytokines and chemokines with pattern #1 (i.e., 317 IL-1Ra, IL-6, IL-8; MCP-1, G-CSF, GM-CSF, and MIP-1β). Pattern #3 gathers only mRNA 318 319 markers linked to both pro- and anti-inflammatory response. Pattern #4 displays specific biomarkers not shared with any other clusters (i.e., Galectin-9, SuPAR, MIF, and Ferritin). 320 Similarly, pattern #5 has its specific biomarkers (RANTES, sTREM-1). These 5 patterns 321 allowed to build 6 clusters of patients with homogeneous biological profiles. The S6 Table 322 displays the scores of the 5 patterns within each cluster of patients. The use of a k-means 323 324 algorithm (non-hierarchical method), with the number of clusters set to 6, led to similar clustering as with the Ward method, with satisfactory agreement (Carmer's V = 0.63). Similar 325 clustering solutions were found with analysis of a random 50% of the sample (Cramer's V =326 0.59). These results support the robustness of the six clusters. 327

The Table 2 shows the criteria of the PIRO profile of sepsis. "Predisposition" items of the PIRO system differed moderately across clusters. Among the "insult", "response", and "organ failure" categories, the most different items between clusters were infection certainty, blood lactate

levels, serum creatinine levels, urinary output, survival, circulatory and renal SOFA sub-scores, 331 332 and use of renal replacement therapy, vaso-pressors and steroids. The Table 3 shows that the levels of the 38 individual circulating biomarkers differed markedly across the clusters and that 333 biomarkers of the same category (pro-inflammatory, anti-inflammatory, adaptive immunity) 334 displayed consistent values within each cluster. In these tables, the color code (from dark red 335 to high level, to dark blue for low level) illustrates the differences within each item of the 336 clusters. Based on these comparisons, six clusters can be distinguished according to the 337 certainty level of the causal infection, the existence of inflammation, use of renal and/or 338 hemodynamic support, pro-inflammatory and anti-inflammatory activity, and markers of 339 340 adaptive profile. Four clusters (clusters #2, #3, #4 and #6) were associated with high mortality (> 30%) and a low adaptive profile (Table 2), and represented 53% of the cohort (Fig 2). 341 Clusters #2 and #6 exhibited both high levels of inflammatory and anti-inflammatory mediators. 342 but differed with regards to CRP and ferritin, #3 displayed anti-inflammatory mediators at low 343 level, and #4 displayed both inflammatory and anti-inflammatory mediators at low level (Fig 344 2). 345

346

Fig 2. Distribution and description of the clusters in the cohort. All the clusters display
different characteristics in terms of parameters of the PIRO system, of circulating biomarkers
and outcome.

	Cluster 1		Cluster 1		Cluster 2		Cluster 3		Cluster 4	Cluster 5				
PIRO category	n		86		43		34		18		11		11	-
Variable	unit	med or %	[Q1-Q3]	-										
Predisposition	1	1		1			1		1			1		p value
Age	years	64	[52-74]	63	[52-77]	70	[58-78]	54	[38-69]	74	[49-84]	77	[63-87]	0.02
BMI	kg/m²	26.1	[21.4-31.4]	24.8	[20.9-27.8]	26.3	[23.9-30.4]	24.5	[20.2-24.5]	27.2	[22.8-37.2]	24.6	[22.7-28.8]	0.35
Male sex	%	62%		77%		67%		83%		45%		64%		0.18
Mc Cabe score (% > 5 years)	%	72%		84%		73%		83%		91%		64%		0.19
COPD	%	24%		28%		21%		6%		9%		9%		0.36
Cardiac insufficiency	%	9%		12%		18%		6%		9%		0%		0.66
Diabetes	%	20%		12%		29%		17%		28%		28%		0.42
Chronic renal insufficiency	%	5%		5%		26%		0%		0%		27%		0.001
Solid tumor	%	15%		12%		18%		6%		18%		18%		0.82
Hematologic malignancy	%	15%		20%		17%		0%		0%		0%		0.83
Chronic hepatic insufficiency	%	10%		2%		9%		11%		0%		9%		0.51
Any prior disease	%	56%		46%		79%		39%		54%		64%		0.03
Insult	1	1		-1			1	-		1	-	1	-	
at inclusion GPC infection	%	7%		16%		12%		11%		9%		9%		0.65
GNB infection	%	37%		65%		65%		67%		54%		45%		0.01
Pneumonia	%	44%		56%		56%		67%		45%		18%		0.2
Intra-abdominal infection	%	2%		12%		3%		11%		9%		9%		0.12
UTI	%	3%		12%		18%		0%		0%		27%		0.01

## 350 Table 2 : Value of each clinical criterion of the PIRO profile of sepsis and outcome in each cluster

Co	nfirmed infection as a cause	%	53%		88%		85%		83%		64%		54%		0.0001
Response		I										1			
at inclusion	Temperature	°C	38.2	[37.5-38.7]	37.9	[37.4-38.7]	38.3	[37.8-38.9]	39,0	[38.0-39.3]	38.6	[38.2-40.0]	38.2	[37.5-38.9]	0.04
	Lymphocyte count	/mm³	960	[690-1,540]	820	[500-1,190]	910	[525-1,200]	990	[860-1,200]	700	[540-1,390]	1,085	[685-1,695]	0.29
	Blood platelets	10³/mm³	170	[129-252]	171	[131-215]	222	[145-306]	252	[203-379]	225	[145-293]	95	[72-156]	0.008
	Prothrombin time	%	71	[62-84]	69	[57-80]	69	[58-78]	74	[61-82]	83	[76-87]	35	[28-40]	0.001
	Blood lactates	meq/L	1.35	[0.90-1.80]	2,00	[1.40-2.70]	1.55	[1.35-2.80]	1.35	[0.90-2.30]	1.45	[0.80-2.30]	2.9	[2.30-4.50]	0.0002
	PaO2	mmHg	94	[74-123]	79	[62-123]	85	[74-106]	86	[77-100]	71	[57-125]	95	[81-168]	0.34
	FiO2	%	35	[30-50]	47	[30-80]	40	[30-55]	40	[30-50]	30	[24-39]	50	[40-70]	0.05
	PaC02	mmHg	41	[34-47]	40	[34-48]	39	[34-49]	39	[34-42]	31	[27-36]	36	[31-47]	0.03
	Serum creatinin	µmol/L	90	[70-150]	120	[75-195]	195	[90-280]	85	[80-140]	140	[80-220]	260	[220-520]	0.0007
	Blood hematocrit	%	34.2	[29.0-39.4]	35.7	[29.9-40.0]	29.6	[27.2-33.0]	28.4	[25.1-30.4]	32.8	[28.5-38.1]	31.2	[29.2-38.5]	0.001
	White blood cell count	/mm³	12,380	[8,700-15,450]	13,450	[10,220-18,700]	14,350	[11,300-19,300]	15,600	[9,200-18,800]	13,900	[8,200-21,700]	14,000	[10,140-40,300]	0.32
	Respiratory rate	/min	25	[21-31]	25	[22-30]	29	[23-33]	30	[27-33]	37	[28-40]	26	[21-34]	0.006
	Heart rate	/min	100	[91-111]	112	[98-128]	115	[98-139]	112	[102-121]	111	[99-116]	110	[98-148]	0.03
	Mean arterial pressure	mmHg	75	[67-89]	67	[60-97]	71	[59-98]	82	[70-101]	81	[66-113]	59	[46-65]	0.009
	Urinary output	L/24h	1,200	[700-1,700]	1,442	[930-1,990]	1,075	[400-2,075]	1,900	[1,500-2,275]	2,125	[1,750-2,300]	85	[5-400]	0.0001
	SAPS II score	points	55	[49-61]	52	[49-61]	55	[49-60]	51	[50-57]	53	[44-59]	59	[56-61]	0.34
over the ICU stay	acquired pneumonia	%	8%		14%		12%		22%		9%		9%		0.59
	acquired bacteremia	%	2%		2%		3%		6%		9%		18%		0.12
Organ failure			1			1				1			•		
over the ICU stay	Total SOFA score	points	5	[2-5]	6	[4-10]	5	[4-9]	3	[2-7]	7	[4-8]	11	[10-14]	0.0001
	Respiratory SOFA score	points	2	[1-3]	2	[2-3]	2	[1-3]	2	[2-3]	2	[1-3]	2	[2-3]	0.2
	Neurological SOFA score	points	0	[0-1]	0	[0-3]	0	[0-1]	0	[0-0]	1	[0-4]	0	[0-2]	0.24
	Circulatory SOFA score	points	0	[0-0]	0	[0-3]	0	[0-3]	0	[0-0]	0	[0-0]	4	[1-4]	0.0001

Hepatic SOFA score	points	0	[0-0]	0	[0-0]	0	[0-0]	0	[0-0]	0	[0-2]	2	[0-2]	0.13
Coagulation SOFA score	points	0	[0-1]	0	[0-1]	0	[0-0]	0	[0-0]	0	[0-1]	1	[3-4]	0.1
Kidney SOFA score	points	0	[0-1]	0	[0-2]	1	[1-2]	0	[0-0]	1	[1-4]	4	[3-4]	0.0001
Mechanical ventilation	%	65%		86%		76%		94%		54%		78%		0.02
Non invasive ventilation	%	7%		2%		3%		0%		27%		11%		0.06
Vaso-active drugs	%	30%		58%		47%		12%		9%		73%		0.0001
Renal replacement therapy	%	2%		2%		24%		0%		0%		45%		0.0001
Low doses steroid therapy	%	1%		19%		15%		0%		9%		27%		0.0005
Outcome														
Death at ICU discharge	%	15%		33%		33%		44%		18%		82%		0.0001

351 The clinical criteria are sorted according to the PIRO classification system. In each raw, the dark red color indicates the highest value and dark

blue color indicates the lowest value, for those variables which are the most significantly different across the clusters.

		Cluster 1		Cluster 2		Cluster 3		Cluster 4		Cluster 5		Cluster 6		
Biomarker category		n=86		n=43		n=34		n=18		n=11		n=11		-
Variable	unit	med	[Q1-Q3]	med	[Q1-Q3]	med	[Q1-Q3]	med	[Q1-Q3]	med	[Q1-Q3]	med	[Q1-Q3]	p value
Inflammatory mediators or biomarkers							1							1
Cytokines														
TNF-α	ng/L	10	[10-10]	10	[10-10]	10	[10-10]	10	[10-10]	10	[10-10]	10	[10-220]	0.0001
TNF-α RNA	CNRQ	0.015	[0.012-0.018]	0.017	[0.011-0.022]	0.013	[0.007-0.019]	0.008	[0.006-0.010]	0.018	[0.014-0.023]	0.009	[0.004-0.016]	0.0001
IL-16 RNA	CNRQ	0,008	[0.006-0.011]	0.008	[0.005-0.008]	0.006	[0.005-0.013]	0.004	[0.003-0.005]	0.013	[0.009-0.018]	0.004	[0.002-0.009]	0.0001
IL-18	ng/L	45.2	[16.1-80.7]	53.8	[35.9-97.4]	77.4	[38.7-197.1]	46.6	[29.2-72.3]	123.5	[123.5-368.0]	365.0	[333.7-924.3]	0.0001
IL-15	ng/L	2.5	[2.50-2.50]	2.5	[2.50-2.50]	2.5	[2.50-2.50]	2.5	[2.50-2.50]	48.4	[2.5-90.9]	25.7	[6.7-107.4]	0.0001
IL-6	ng/L	45	[15-149]	1,298	[327-5,344]	119	[44-342]	59	[24-485]	873	[193-2107]	8,333	[1,259-85,509]	0.0001
GM-CSF	ng/L	9.8	[4.0-28.9]	609.1	[64.0-1,754.9]	13.5	[4.0-53.9]	4.0	[4.0-43.2]	18.2	[4.0-575.8]	411.5	[293.0-13,027.0]	0.0001
Chemokines and receptors										1	1			1
MCP-1	ng/L	49	[5-85]	173	[98-927]	54	[5-84]	75	[44-192]	240	[48-379]	342	[127-11,415]	0.0001
MIF	μg/L	8.5	[4.4-14.2]	5.1	[2.7-7.5]	15.5	[6.7-22.2]	11.7	[7.7-23.9]	12.5	[8.7-24.3]	42.0	[23.3-48.6]	0.0001
Rantes CCL5	μg/L	14.2	[9.6-14.2]	10.4	[7.3-16.3]	12.1	[8.1-15.7]	15.8	[10.4-19.1]	57.6	[22.4-115.1]	6.6	[4.1-31.6]	0.0001
IP-10	ng/L	165	[59-363]	284	[117-552]	505	[216-904]	282	[185-800]	6,034	[1,631-21,478]	836	[580-60,981]	0.0001
IL-8	ng/L	12.5	[4.0-23.8]	73.4	[31.6-337.2]	26.0	[213.5-47.9]	14.3	[9.4-26.0]	24.4	[4.0-137.0]	494.0	[187.0-1,494.0]	0.0001
MIP-18	ng/L	39	[20-60]	88	[40-243]	62	[24-132]	53	[37-73]	305	[70-450]	149	[119-1,229]	0.0001
CX3CR1 RNA	CNRQ	14.1	[10.9-18.9]	7.2	[4.0-12.5]	9.5	[4.7-16.0]	5.7	[4.1-7.0]	10.4	[6.8-16.4]	4.2	[1.7-7.6]	0.0001
Others							•		1	1	1			1

## **Table 3 : Value of each circulating biomarker of sepsis in each cluster.**

C reactive protein	mg/L	146	[68-203]	296	[241-331]	265	[194-346]	235	[154-318]	310	[265-454]	208	[153-249]	0.0001
Procalcitonin	μg/L	1.3	[1.2-1.3]	2.7	[1.4-6.3]	2.2	[1.6-4.5]	1.8	[1.5-2.2]	1.6	[1.4-5.3]	7.2	[2.8-18.9]	0.0001
SuPAR	ng/L	6.14	[4.35-8.34]	7.27	[5.41-11.49]	15.33	[12.89-18.27]	11.58	[6.4-14.2]	10.4	[7.0-14.1]	20.6	[11.8-35.0]	0.0001
Visfatin	μg/L	5.56	[4.52-7.00]	4.98	[4.22-5.85]	5.47	[4.42-6.75]	4.45	[4.07-5.34]	5.17	[4.50-6.03]	38.46	[10.31-140.11]	0.0001
PSP	ng/L	69	[45-139]	325	[139-613]	341	[145-1,121]	144	[111-321]	115	[66-257]	780	[349-1,538]	0.0001
sB7-H6	ng/L	24.6	[16.5-27.7]	27.5	[18.3-31.4]	23.9	[15.9-29.1]	19.2	[11.2-26.5]	28.2	[17.7-35.8]	0.0	[0.0-0.0]	0.0004
MMP-8	μg/L	20	[10-45]	77	[47-167]	85	[30-192]	46	[20-110]	74	[64-197]	198	[93-212]	0.0001
sTREM-1	μg/L	2.2	[1.3-4.0]	4.1	[2.0-5.5]	4.7	[3.1-6.5]	1.0	[0.6-2.6]	2.3	[1.4-4.3]	4.3	[3.3-8.6]	0.0001
HMGB1 RNA	CNRQ	3.64	[3.14-4.22]	3.58	[3.03-4.05]	3.89	[3.19-3.89]	3.22	[2.47-3.61]	3.35	[2.53-4.03]	3.81	[3.00-4.45]	0.03
Ferritin	μg/L	1	[1-2]	2	[1-2]	211	[117-434]	248	[165-501]	273	[178-516]	960	[732-1,075]	0.0001
Galectin 9	μg/L	5.7	[3.4-7.4]	5.8	[3.2-8.5]	12.5	[9.4-17.6]	8.2	[5.0-12.8]	8.1	[6.6-12.5]	25.7	[19.2-35.9]	0.0001
\$100A9 RNA	CNRQ	15.4	[11.4-15.4]	28.2	[21.7-36.5]	24.1	[17.0-28.3]	14.6	[9.7-20.3]	24.3	[14.1-32.7]	30.2	[18.9-37.4]	0.0001
Anti-inflammatory mediators				I						L				1
IL-1Ra	CNRQ	15.0	[15.0-15.0]	18.3	[15.0-620.4]	15.0	[15.0-16.7]	15.0	[15.0-15.0]	215.4	[15.0-632.3]	3,174.8	[927.0-5,062.0]	0.0001
11-10	ng/L	4.0	[4.0-4.0]	4.0	[4.0-10.9]	4.0	[4.0-4.0]	4.0	[4.0-4.0]	4.0	[4.0-4.0]	107.9	[51.3-321.7]	0.0001
IL-10 RNA	CNRQ	0.17	[0.12-0.24]	0.60	[0.41-1.13]	0.23	[0.12-0.40]	0.09	[0.07-0.12]	0.41	[0.27-0.78]	0.37	[0.19-0.57]	0.0001
Adaptive immunity												I		1
HLA-DR RNA	CNRQ	0.34	[0.27-0.42]	0.15	[0.10-0.20]	0.24	[0.11-0.41]	0.18	[0.15-0.21]	0.29	[0.27-0.42]	0.28	[0.04-0.36]	0.0001
CD74 RNA	CNRQ	0.59	[0.46-0.71]	0.28	[0.18-0.40]	0.36	[0.19-0.63]	0.27	[0.27-0.32]	0.59	[0.45-0.72]	0.26	[0.08-0.53]	0.0001
LILRB2 RNA	CNRQ	0.83	[0.67-0.99]	0.93	[0.82-1.28]	0.76	[0.68-0.94]	0.42	[0.35-0.54]	1.12	[0.71-1.32]	0.79	[0.48-1.09]	0.0001
CD3 RNA	CNRQ	1.18	[0.87-1.51]	0.56	[0.34-0.74]	0.49	[0.33-1.06]	0.56	[0.44-1.12]	0.79	[0.49-1.02]	0.21	[0.20-0.53]	0.0001
Pathogen associated molecular patterns	1													
Peptidoglycan	μg/L	2.19	[0.75-3.31]	2.79	[1.63-3.79]	2.63	[1.75-3.90]	2.64	[2.01-3.53]	4.44	[2.76-6.08]	1.89	[0.75-2.71]	0.001

355 The individual biomarkers are sorted according to their role in inflammation, anti-inflammation or adaptive immune profile. In each raw, the dark

red color indicates the highest value and dark blue color indicates the lowest value. CNRQ = Calibrated Normalized Relative Quantity

## 357 **Discussion**

In a prospective cohort of ICU patients suspected of sepsis, through the levels of circulating biomarkers indicative of pro-inflammation, anti-inflammation or adaptive immunity and the use of unsupervised statistical approaches, we individualized six different clusters of patients with homogeneous profiles regarding sepsis clinical staging. These clusters presented with different immune and clinical profiles, making them potential targets for individualized therapies.

Sepsis is a life-threatening condition elicited by various infectious conditions, with a heterogeneous presentation, and an outcome impacted by both the pathogen and host characteristics [1]. This phenotypic polymorphism led to the proposal of the PIRO classification and staging system in 2001 to help individualize future therapies [12]. A better understanding of subgroups within the heterogenous host response to infection is important both for a better understanding of the biology of sepsis but also for the next generation of trials of more precise interventions for sepsis.

Given the heterogeneity of both clinical and immune presentation of sepsis and the multiple 371 failures of trials in unselected populations [13], a cluster approach has been used by several 372 authors [31]. In these studies, clustering was based either on phenotypes to describe different 373 clinical profiles without addressing immune mechanisms of sepsis, and mostly provide 374 differences in prognosis, or on endotypes, deriving subclasses from genome-wide expression 375 profiling [31]. The latter option, as endotypes are markers of pathophysiological pathways, may 376 377 help to predict treatment responsiveness [16]. Wong *et al.* identified three pediatric septic shock subclasses named A, B and C [32]. Subclass A displayed a depressed expression of adaptive 378 379 immune system, of glucocorticoid signaling and zinc-related biology and associated with higher severity and mortality. Scicluna et al. identified four sepsis subclasses named Mars 1 to 4 [15]. 380

Subclass Mars1, with a higher mortality, displayed reduced expression of genes involved in 381 382 innate and immune functions. Subclass Mars3, with a better survival, displayed increased expression of adaptive immune or T-cell functions. Davenport et al. identified two sepsis 383 subclasses named SRS1 and SRS2 [33], with SRS1 characterized by a higher mortality and 384 decreased expression of immune functions. Finally, based on gene activation profiles, Sweeney 385 et al. identified three sepsis subclasses named inflammopathic, adaptive and coagulopathic 386 [34]. The adaptive subgroup was associated with lower severity and mortality, and the 387 coagulopathic subgroup with higher mortality and clinical coagulopathy. In our study, we also 388 derived clusters from endotypes, but these were assessed with biomarkers made of molecules 389 390 previously documented to play a role the pathophysiology of sepsis. We used unsupervised statistical approaches to set up clusters, because they explore data without a priori classification 391 [35]: principal component analysis, to determine different patterns, hierarchical clustering to 392 group the patients and k-means algorithm to assess the internal validity of the clusters. 393

In our cohort, two clusters (#1 and #5) had a low level of organ dysfunction and mortality. 394 395 Clusters #2 and #3 displayed high level of infection certainty and inflammation, and differed by their anti-inflammatory status, consistent with the concept of compensatory anti-396 inflammation and its heterogeneity [8]. Cluster #4 displayed a low level of innate response 397 398 despite high severity and high ferritin levels. Lastly, two clusters, #5 and #6, were associated with very specific phenotypes, one (#5) with pro and anti-inflammatory high-level profile 399 400 despite low mortality, and the second one (#6) with high immune alteration and particularly high level of ferritin. 401

Half our cohort belongs to clusters associated with a high mortality rate. They are characterized
by their low adaptive profile at sepsis diagnosis. They differ between themselves by their
respective levels of certainty of the causal infection, of CRP and ferritin levels, of renal and
hemodynamic level of support, and of pro-inflammatory and anti-inflammatory activities. Each

of these characteristics may be available at bedside in parallel of the assessment of infection,
organ dysfunction, pro- (for example TNFα and/or IL-18) and anti-inflammatory (for example
IL-1Ra and/or IL-10) cytokines, and markers of adaptive function (for example HLA-DR).
These criteria are relatively simple and should be validated in external cohorts before they can
be used as inclusion criteria in prospective trials.

Our study has limitations. First, several biomarkers, including some recently described, were 411 412 not assessed in this cohort, and should be assessed in similar conditions. Especially, biomarkers more specific of endothelial dysfunction or coagulation activation were underrepresented in our 413 panel. Second, although at risk of sepsis, several categories of patients were not included in the 414 415 cohort, particularly those with prior immune suppression, whose innate and adaptive responses are likely different from the immunocompetent patients. These patients should be investigated 416 using a similar approach. Third, while the generalizability of our study may be reinforced by 417 its multicenter design and the use of internal validity assessments, we did not perform external 418 validation in a separate cohort. This is particularly important for the groups with small numbers 419 420 of patients in our cohort.

421

## 422 Conclusion

In a prospective cohort of ICU patients with suspected sepsis, we individualized clusters of
patients which may be described with criteria commonly used to stage sepsis in routine practice.
As these clusters are based on the patterns of circulating biomarkers, whether they might help
to predict treatment responsiveness should be addressed in further studies.

427

428

429

## 430 Acknowledgements

We sincerely thank Drs Anne-Françoise Rousseau, Bernard Lambermont and François Jouret
for their critical review, Céline Féger, MD (EMIBiotech) and Séverine Marck for their editorial
support for this manuscript.

#### 434 Collaborators

435 Members of the Combined Approach for The eArly diagnosis of INfection in sepsis436 (CAPTAIN) study group:

Sébastien JACQMIN, Didier JOURNOIS, Alix LAGRANGE, Gabrielle PINOT de 437 VILLECHENON (Hôpital Européen Georges Pompidou, AP – HP - Université Paris 438 Descartes, Service d'Anesthésie-Réanimation), Nadia AISSAOUI, Jean-Luc DIEHL, 439 Emmanuel GUEROT, Marion VENOT (Hôpital Européen Georges Pompidou, AP - HP -440 441 Université Paris Descartes, Service de Réanimation Médicale), Olfa HAMZAOUI, Dominique PRAT, Benjamin SZTRYMF (Hôpital Antoine Béclère, AP – HP - Université Paris Sud, 442 Clamart), Djillali ANNANE, Virginie MAXIME, Andrea POLITO (Hôpital Raymond 443 Poincaré, AP – HP - Université Paris Ile de France Ouest, Service de Réanimation Médico-444 chirurgicale), Belaïd BOUHEMAD, Cédric BRUEL, Frédéric ETHUIN, Julien FOURNIER, 445 Maïté GARROUSTE-ORGEAS, Charles GREGOIRE, Nicolas LAU, Benoît MISSET, 446 François PHILIPPART (Groupe Hospitalier Paris Saint Joseph, Service de Réanimation), 447 Jean-Pierre BEDOS, Pierrick CROSNIER, Virginie LAURENT, Sybille MERCERON 448 449 (Hôpital André Mignot, Versailles, Service de Réanimation médico-chirurgicale), Elsa BOURNAUD, Laurence LECOMTE, Jean-Marc TRELUYER, (Hôpital Cochin, AP-HP -450 Université Paris Descartes, Unité de Recherche Clinique), Alexandre PACHOT, Javier 451

452 YUGUEROS-MARCOS, Laurent ESTEVE, Sophie BLEIN, Virginie MOUCADEL
453 (bioMérieux, Lyon & Grenoble), Myriam BEN BOUTIEB, Alexandra ROUQUETTE, Joël
454 COSTE (*Hôpital Cochin, AP-HP - Université de Paris, Unité de Biostatistique et d'Epidémiologie*), Minou ADIB-CONGUY, Jean-Marc CAVAILLON, Catherine FITTING,
456 Marianna PARLATO, Virginie PUCHOIS, Fernando SOUZA-FONSECA-GUIMARAES
457 (Institut Pasteur, Paris, Unit Cytokines & Inflammation).

458

## 459 **References**

- 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The
  Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA.
  2016;315:801–810.
- 463 2. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392:75–87.

3. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis
Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.
Intensive Care Med. 2017;43:304–377.

467 4. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the
468 SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results
469 of a multicenter, prospective study. Working group on "sepsis-related problems" of the
470 European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–1800.

5. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G, et al.
Current gaps in sepsis immunology: new opportunities for translational research. Lancet Infect
Dis. 2019;19:e422–e436.

- 474 6. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–
  475 1045.
- 476 7. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular
- dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–874.
- 478 8. Adib-Conquy M, Cavaillon J-M. Compensatory anti-inflammatory response syndrome.
- 479 Thromb Haemost. 2009;101:36–47.
- 480 9. Angus DC, Burgner D, Wunderink R, Mira J-P, Gerlach H, Wiedermann CJ, et al. The PIRO

481 concept: P is for predisposition. Crit Care. 2003;7:248–251.

- 482 10. Toubiana J, Courtine E, Pène F, Viallon V, Asfar P, Daubin C, et al. IRAK1 functional
- 483 genetic variant affects severity of septic shock. Crit Care Med. 2010;38:2287–2294.
- 11. Bedos J-P, Varon E, Porcher R, Asfar P, Le Tulzo Y, Megarbane B, et al. Host-pathogen
  interactions and prognosis of critically ill immunocompetent patients with pneumococcal
  pneumonia: the nationwide prospective observational STREPTOGENE study. Intensive Care
  Med. 2018;44:2162–2173.
- Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001
  SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care
  Med. 2003;29:530–538.
- 491 13. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ.
  492 2016;353:i1585.
- 493 14. Cavaillon J-M, Singer M, Skirecki T. Sepsis therapies: learning from 30 years of failure of
  494 translational research to propose new leads. EMBO Mol Med. 2020;12:e10128.

29

495 15. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL,

496 et al. Classification of patients with sepsis according to blood genomic endotype: a prospective

497 cohort study. Lancet Respir Med. 2017;5:816–826.

498 16. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX. Toward Smarter Lumping and

499 Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome

500 Clinical Trial Design. Am J Respir Crit Care Med. 2016;194:147–155.

501 17. Vincent J-L, Francois B, Zabolotskikh I, Daga MK, Lascarrou J-B, Kirov MY, et al. Effect
502 of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis503 Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA. 2019;321:1993–
504 2002.

Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, et al. Interleukin-7
restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight.
2018;3:e98960.

19. Dupuy A-M, Philippart F, Péan Y, Lasocki S, Charles P-E, Chalumeau M, et al. Role of
biomarkers in the management of antibiotic therapy: an expert panel review: I - currently
available biomarkers for clinical use in acute infections. Ann Intensive Care. 2013;3:22.

20. Miller RR, Lopansri BK, Burke JP, Levy M, Opal S, Rothman RE, et al. Validation of a
Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory
Response Syndrome in the ICU. Am J Respir Crit Care Med. 2018;198:903–913.

21. Parlato M, Philippart F, Rouquette A, Moucadel V, Puchois V, Blein S, et al. Circulating
biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the
CAPTAIN prospective multicenter cohort study. Intensive Care Medicine. 2018;44:1061–
1070.

- 518 22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
- 519 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
- 520 guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577.
- 521 23. Parlato M, Cavaillon J-M. Host response biomarkers in the diagnosis of sepsis: a general
- 522 overview. Methods Mol Biol. 2015;1237:149–211.
- 523 24. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative

quantification framework and software for management and automated analysis of real-time

- 525 quantitative PCR data. Genome Biol. 2007;8:R19.
- 526 25. Marshall JC. The PIRO (predisposition, insult, response, organ dysfunction) model: toward
  527 a staging system for acute illness. Virulence. 2014;5:27–35.
- 26. Cohen J, Vincent J-L, Adhikari NKJ, Machado FR, Angus DC, Calandra T, et al. Sepsis: a
  roadmap for future research. Lancet Infect Dis. 2015;15:581–614.
- 53027.IDSAPracticeGuidelines.Availablefrom:531http://www.idsociety.org/PracticeGuidelines/?q=&ref=taxonomy\_map%3B(%22%2FIDSA%5322FSite+Map%2FGuidelines%2FPatient+Care%2FIDSA+Practice+Guidelines%2FInfections+533By+Organ+System-81567%2FLower%2FUpper+Respiratory%22)%3BOrgan+System.
- 534 Accessed 15 Feb 2018.

524

- 28. Coste J, Bouée S, Ecosse E, Leplège A, Pouchot J. Methodological issues in determining
  the dimensionality of composite health measures using principal component analysis: case
  illustration and suggestions for practice. Qual Life Res. 2005;14:641–654.
- 538 29. Everitt BS. Unresolved Problems in Cluster Analysis. Biometrics. 1979;35:169–181.

30. Wastell DG, Gray R. The numerical approach to classification: a medical application to
develop a typology for facial pain. Stat Med. 1987;6:137–146.

31. DeMerle KM, Angus DC, Baillie JK, Brant E, Calfee CS, Carcillo J, et al. Sepsis
Subclasses: A Framework for Development and Interpretation. Crit Care Med. 2021;49:748–
759.

32. Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, et al. Identification
of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med.
2009;7:34.

33. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al.
Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort
study. Lancet Respir Med. 2016;4:259–271.

34. Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, et al. Unsupervised
Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust
Clusters. Crit Care Med. 2018;46:915–925.

35. Omorou AY, Coste J, Escalon H, Vuillemin A. Patterns of physical activity and sedentary
behaviour in the general population in France: cluster analysis with personal and socioeconomic
correlates. J Public Health (Oxf). 2016;38:483–492.

556

## 557 Supporting information

S1 Table. STROBE—Checklist of items that should be included in reports of *cohort studies.* An Explanation and Elaboration article discusses each checklist item and gives
 methodological background and published examples of transparent reporting. The STROBE

561	checklist is best used in conjunction with this article (freely available on the Web sites of PLoS
562	Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at
563	http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the
564	STROBE Initiative is available at http://www.strobe-statement.org.
565	
566	S2 Table. Kits for soluble markers concentration measure.
567	
568	S3 Table. Lower and Upper limits of Quantification for each plasma biomarker.
500	Se fusio Lower and Opper mines of Quantification for each paisma stomather
569	
570	S4 Table. Primer and probe designs for mRNA biomarkers.
571	
572	S5 Table. Circulating biomarkers with a loading $> 0.40$ or $< -0.40$ in each main
573	independent patterns obtained after principal component analysis. The 5 patterns where
574	those which explained the largest part of the variance (59 % in total). For each pattern, the
575	individual biomarkers with high loadings are displayed. The individual biomarkers are sorted
576	by the absolute value of their loading. Loadings are interpretable as correlation coefficients
577	between patterns and original biomarkers.
578	
579	<b>S6 Table. Value of each pattern of biomarkers in the identified clusters (med [Q1-Q3]).</b> In
580	each raw, the dark red color indicates the highest value and dark blue color indicates the lowest
581	value.
582	

#### 583 S1 Fig. Distribution of missing values and determination of the cut-off to create binary

- variables. Lower part of the figure: category of the value of each biomarker for each patient.
- 585 Color code: white: value between the LLoQ and the ULoQ ; orange = value under the LLoQ;
- 586 blue = value over the ULoQ; grey = undetermined value.
- 587 X axis: biomarkers
- 588 Y axis: patients
- 589 Upper part of the figure:
- 590 Y axis: percentage of patients with a value below the LLoQ
- 591 The plain blue line indicates the separation between biomarkers treated as binary variables (left
- side of the line) and as continuous variables (right side of the line). The dotted line indicates
- the cut-off of 40%, over which the biomarker was treated as a binary value.



## Figure 1

#### Cluster #5 (5% of the patients)



Cluster #6 (5% of the patients)

# Figure 2